- 10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
- 10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
- 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
- 10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
- 10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
- 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
- 10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
- 10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.93 |
---|---|
High | 27.14 |
Low | 26.30 |
Bid | 25.50 |
Offer | 28.63 |
Previous close | 27.52 |
Average volume | 1.96m |
---|---|
Shares outstanding | 119.17m |
Free float | 101.89m |
P/E (TTM) | -- |
Market cap | 3.28bn USD |
EPS (TTM) | -2.18 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼